The cost of not re-testing: HIV misdiagnosis in the ART ‘test-and-offer’ era
File(s)cix341.pdf (502.71 KB)
Published version
Author(s)
Eaton, JW
Johnson, CC
Gregson, S
Type
Journal Article
Abstract
We compared estimated costs of retesting human immunodeficiency virus (HIV)-positive persons before antiretroviral therapy (ART) initiation to the costs of ART provision to misdiagnosed HIV-negative persons. Savings from averted unnecessary ART costs were greater than retesting costs within 1 year using assumptions representative of HIV testing performance in programmatic settings. Countries should implement re-testing before ART initiation.
Date Issued
2017-04-24
Date Acceptance
2017-04-20
Citation
Clinical Infectious Diseases, 2017, 65 (3), pp.522-525
ISSN
1537-6591
Publisher
Oxford University Press (OUP)
Start Page
522
End Page
525
Journal / Book Title
Clinical Infectious Diseases
Volume
65
Issue
3
Copyright Statement
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of
America. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
America. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
License URL
Sponsor
Bill & Melinda Gates Foundation
Grant Number
OPP1131208
Subjects
Science & Technology
Life Sciences & Biomedicine
Immunology
Infectious Diseases
Microbiology
HIV testing
misdiagnosis
antiretroviral treatment
cost-benefit analysis
SUB-SAHARAN AFRICA
HIV
PROGRAM
06 Biological Sciences
11 Medical And Health Sciences
Publication Status
Published